Yıl: 2021 Cilt: 27 Sayı: 2 Sayfa Aralığı: 212 - 214 Metin Dili: İngilizce DOI: 10.4274/tnd.2021.94762 İndeks Tarihi: 19-01-2022

No Intraparenchymal Mass Lesion in a Patient with Lung Adenocarcinoma with Treatment-Resistant Seizures: What Next?

Öz:
Leptomeningeal carcinomatosis (LMC) is a relatively rare complication of advanced-stage cancer. The diagnosis of LMC is based on clinical and radiologic findings and cytologic examinations. The diagnosis may be difficult because the clinical findings may be subtle initially, and the specificity of the diagnostic modalities is low. A 41-year-old male patient with metastatic lung adenocarcinoma presented with headache, confusion, and treatment-resistant seizures. There was no intraparenchymal mass lesion or leptomeningeal contrast enhancement in brain magnetic resonance imaging. The presence of LMC was demonstrated in a cytopathologic examination of cerebrospinal fluid. The seizures were controlled with antiepileptic treatment, but the patient was referred to the palliative care center due to poor oncologic prognosis.
Anahtar Kelime:

Tedaviye Dirençli Nöbetlerden Muzdarip Akciğer Adenokarsinomlu Bir Hastada İntraparankimal Kitle Lezyonu Yok: Ne Yapmalı?

Öz:
Leptomeningeal karsinomatozis (LMK), ileri evre kanserlerin görece nadir bir komplikasyonudur. Bu tanı klinik ve radyolojik bulgular ile sitolojik incelemelere dayanarak koyulur. Klinik bulguların başlangıçta silik olabilmesi ve tanı modalitelerinin spesifisitesinin düşük olması nedeniyle tanı koymada güçlük yaşanabilir. Metastatik akciğer adenokarsinomlu, 41 yaşında bir erkek hasta baş ağrısı, konfüzyon ve tedaviye dirençli nöbetlerle başvurdu. Beyin manyetik rezonans görüntülemesinde intraparankimal kitle lezyonu ya da leptomeningeal kontrast tutulumu saptanmadı. Beyin omurilik sıvısının sitopatolojik incelemesi ile LMK varlığı gösterildi. Antiepileptik tedavi ile nöbetleri kontrol altına alındı ancak onkolojik prognozunun kötü olması nedeniyle hasta, palyatif bakım merkezine sevk edildi.
Anahtar Kelime:

Belge Türü: Makale Makale Türü: Olgu Sunumu Erişim Türü: Erişime Açık
  • 1. Ko Y, Gwak HS, Park EY, et al. Association of MRI findings with clinical characteristics and prognosis in patients with leptomeningeal carcinomatosis from non-small cell lung cancer. J Neurooncol 2019;143:553-562.
  • 2. Hochmair M. Medical treatment options for patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer suffering from brain metastases and/or leptomeningeal disease. Target Oncol 2018;13:269- 285.
  • 3. Fox BD, Cheung VJ, Patel AJ, Suki D, Rao G. Epidemiology of metastatic brain tumors. Neurosurg Clin N Am 2011;22:1-6, v.
  • 4. Wang N, Bertalan MS, Brastianos PK. Leptomeningeal metastasis from systemic cancer: Review and update on management. Cancer 2018;124:21- 35.
  • 5. Nagpal S, Riess J, Wakelee H. Treatment of leptomeningeal spread of NSCLC: a continuing challenge. Curr Treat Options Oncol 2012;13:491- 504.
  • 6. Remon J, Le Rhun E, Besse B. Leptomeningeal carcinomatosis in nonsmall cell lung cancer patients: A continuing challenge in the personalized treatment era. Cancer Treat Rev 2017;53:128-137.
  • 7. Le Rhun E, Galanis E. Leptomeningeal metastases of solid cancer. Curr Opin Neurol 2016;29:797-805.
  • 8. Singh SK, Leeds NE, Ginsberg LE. MR imaging of leptomeningeal metastases: comparison of three sequences. AJNR Am J Neuroradiol 2002;23:817-821.
  • 9. Chamberlain MC. Leptomeningeal metastasis. Curr Opin Oncol 2010;22:627-635.
  • 10. Straathof CS, de Bruin HG, Dippel DW, Vecht CJ. The diagnostic accuracy of magnetic resonance imaging and cerebrospinal fluid cytology in leptomeningeal metastasis. J Neurol 1999;246:810-814.
  • 11. Maroldi R, Ambrosi C, Farina D. Metastatic disease of the brain: extra-axial metastases (skull, dura, leptomeningeal) and tumour spread. Eur Radiol 2005;15:617-626.
  • 12. Freilich RJ, Krol G, DeAngelis LM. Neuroimaging and cerebrospinal fluid cytology in the diagnosis of leptomeningeal metastasis. Ann Neurol 1995;38:51-57.
  • 13. Kremer S, Abu Eid M, Bierry G, et al. Accuracy of delayed post-contrast FLAIR MR imaging for the diagnosis of leptomeningeal infectious or tumoral diseases. J Neuroradiol. 2006;33:285-291.
  • 14. Misaki K, Nakada M, Hayashi Y, et al. Contrast-enhanced fluid-attenuated inversion recovery MRI is useful to detect the CSF dissemination of glioblastoma. J Comput Assist Tomogr 2001;25:953-956.
  • 15. Glantz MJ, Cole BF, Glantz LK, et al. Cerebrospinal fluid cytology in patients with cancer: minimizing false-negative results. Cancer 1998;82:733-739.
APA Inan B, Tasar Kapakli G, Dericioglu N (2021). No Intraparenchymal Mass Lesion in a Patient with Lung Adenocarcinoma with Treatment-Resistant Seizures: What Next?. , 212 - 214. 10.4274/tnd.2021.94762
Chicago Inan Berin,Tasar Kapakli Gozde Elif,Dericioglu Nese No Intraparenchymal Mass Lesion in a Patient with Lung Adenocarcinoma with Treatment-Resistant Seizures: What Next?. (2021): 212 - 214. 10.4274/tnd.2021.94762
MLA Inan Berin,Tasar Kapakli Gozde Elif,Dericioglu Nese No Intraparenchymal Mass Lesion in a Patient with Lung Adenocarcinoma with Treatment-Resistant Seizures: What Next?. , 2021, ss.212 - 214. 10.4274/tnd.2021.94762
AMA Inan B,Tasar Kapakli G,Dericioglu N No Intraparenchymal Mass Lesion in a Patient with Lung Adenocarcinoma with Treatment-Resistant Seizures: What Next?. . 2021; 212 - 214. 10.4274/tnd.2021.94762
Vancouver Inan B,Tasar Kapakli G,Dericioglu N No Intraparenchymal Mass Lesion in a Patient with Lung Adenocarcinoma with Treatment-Resistant Seizures: What Next?. . 2021; 212 - 214. 10.4274/tnd.2021.94762
IEEE Inan B,Tasar Kapakli G,Dericioglu N "No Intraparenchymal Mass Lesion in a Patient with Lung Adenocarcinoma with Treatment-Resistant Seizures: What Next?." , ss.212 - 214, 2021. 10.4274/tnd.2021.94762
ISNAD Inan, Berin vd. "No Intraparenchymal Mass Lesion in a Patient with Lung Adenocarcinoma with Treatment-Resistant Seizures: What Next?". (2021), 212-214. https://doi.org/10.4274/tnd.2021.94762
APA Inan B, Tasar Kapakli G, Dericioglu N (2021). No Intraparenchymal Mass Lesion in a Patient with Lung Adenocarcinoma with Treatment-Resistant Seizures: What Next?. Türk Nöroloji Dergisi, 27(2), 212 - 214. 10.4274/tnd.2021.94762
Chicago Inan Berin,Tasar Kapakli Gozde Elif,Dericioglu Nese No Intraparenchymal Mass Lesion in a Patient with Lung Adenocarcinoma with Treatment-Resistant Seizures: What Next?. Türk Nöroloji Dergisi 27, no.2 (2021): 212 - 214. 10.4274/tnd.2021.94762
MLA Inan Berin,Tasar Kapakli Gozde Elif,Dericioglu Nese No Intraparenchymal Mass Lesion in a Patient with Lung Adenocarcinoma with Treatment-Resistant Seizures: What Next?. Türk Nöroloji Dergisi, vol.27, no.2, 2021, ss.212 - 214. 10.4274/tnd.2021.94762
AMA Inan B,Tasar Kapakli G,Dericioglu N No Intraparenchymal Mass Lesion in a Patient with Lung Adenocarcinoma with Treatment-Resistant Seizures: What Next?. Türk Nöroloji Dergisi. 2021; 27(2): 212 - 214. 10.4274/tnd.2021.94762
Vancouver Inan B,Tasar Kapakli G,Dericioglu N No Intraparenchymal Mass Lesion in a Patient with Lung Adenocarcinoma with Treatment-Resistant Seizures: What Next?. Türk Nöroloji Dergisi. 2021; 27(2): 212 - 214. 10.4274/tnd.2021.94762
IEEE Inan B,Tasar Kapakli G,Dericioglu N "No Intraparenchymal Mass Lesion in a Patient with Lung Adenocarcinoma with Treatment-Resistant Seizures: What Next?." Türk Nöroloji Dergisi, 27, ss.212 - 214, 2021. 10.4274/tnd.2021.94762
ISNAD Inan, Berin vd. "No Intraparenchymal Mass Lesion in a Patient with Lung Adenocarcinoma with Treatment-Resistant Seizures: What Next?". Türk Nöroloji Dergisi 27/2 (2021), 212-214. https://doi.org/10.4274/tnd.2021.94762